Headlines about ProQR Therapeutics (NASDAQ:PRQR) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProQR Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.7986292530108 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

ProQR Therapeutics (NASDAQ:PRQR) opened at $3.35 on Thursday. The company has a quick ratio of 6.72, a current ratio of 6.72 and a debt-to-equity ratio of 0.20. ProQR Therapeutics has a 12 month low of $2.90 and a 12 month high of $6.90.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. equities analysts anticipate that ProQR Therapeutics will post -1.71 EPS for the current fiscal year.

Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded ProQR Therapeutics from a “sell” rating to a “buy” rating and set a $3.50 price target for the company in a report on Friday, November 24th. ValuEngine downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Leerink Swann reiterated an “outperform” rating and set a $12.00 price target (up previously from $10.00) on shares of ProQR Therapeutics in a report on Tuesday, September 26th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of ProQR Therapeutics in a report on Tuesday, September 26th. Finally, JMP Securities upped their price target on ProQR Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.88.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/30/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-proqr-therapeutics-prqr-stock-price.html.

About ProQR Therapeutics

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Insider Buying and Selling by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.